Valuation: Devonian Health Group Inc.

Market Cap 28.2M 20.11M 17.99M 16.64M 15.07M 1.91B 28.66M 200M 79.21M 1B 75.49M 73.88M 3.17B P/E 2024
-22.2x
P/E 2025 -3.7x
Enterprise Value 21.34M 15.22M 13.61M 12.59M 11.4M 1.45B 21.69M 152M 59.94M 757M 57.13M 55.91M 2.4B EV / Sales 2024
1.11x
EV / Sales 2025 0.65x
Free-Float
87.96%
Yield 2024 *
-
Yield 2025 -
10-20 Devonian Health Gets Health Canada Authorization for Thykamine Clinical Trial in Breast Cancer Patients MT
10-20 Devonian Health Group Inc. Receives Health Canada Authorization to Evaluate Novel Thykamine? Formulation for Prevention of Radiation-Induced Skin Injury in Breast Cancer Patients CI
10-16 Devonian Health "Remains Committed" to US IPO, Listing on NYSE American MT
09-01 Devonian Health Group Strengthens Thykamine Manufacturing Platform With Validated Chemical-Composition Fingerprinting And Biological Potency Assay CI
08-18 Devonian Health Expects to Start Trading on the NYSE American Exchange MT
07-21 Devonian Health Group Receives Health Canada Authorization to Initiate Phase Ii/Iii Pediatric Clinical Trial of Thykamine for Mild-To-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years CI
07-21 Devonian Health Group Receives Health Canada Nod For Thykamine Trial in Children MT
06-30 Devonian Health Posts Narrower Q3 Net Loss MT
06-29 Devonian Health Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2026 CI
03-30 Devonian Health Group Inc. Announces Election of Directors CI
03-25 Devonian Health Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2026 CI
02-19 Devonian Health Group Inc. Reports Human Liver-On-A-Chip Data Demonstrating Disease-Relevant Modulation of Mash by Thykamine, with Dose-Dependent Anti- Fibrotic and Anti-Inflammatory Effects CI
02-17 Devonian Health Group Inc. Advances Thykamine Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls CI
1 day+5.63%
1 week+5.63%
Current month-16.20%
1 month-16.20%
6 months-36.97%
Current year-34.21%
1 week 7.5
Extreme 7.5
7.5
1 month 6.7
Extreme 6.7
8.25
Current year 5.1
Extreme 5.1
14.99
1 year 5.1
Extreme 5.1
15
3 years 4.5
Extreme 4.499991
21
5 years 4.5
Extreme 4.499991
40.8
10 years 4.5
Extreme 4.499991
57
Manager TitleAgeSince
Chief Executive Officer - 2025-06-08
Director of Finance/CFO - 2026-02-01
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 2026-03-26
Director/Board Member 60 2025-11-04
Chairman - 2024-06-02
Date Insider Type Main position Quantity % Market Cap. Importance
4/13/26 Other

Director

0 0%
2/24/26 Tax

Executive/Senior Manager

6,913,160 -
2/24/26 Tax 148,961 5.3860%
Change 5-day change 1-year change 3-year change Capi.($)
+5.63%+5.63%-30.56%-43.18% 14.12M
+0.88%-0.34%+40.64%+73.05% 64.69B
-0.26%+6.91%+11.14%+77.36% 54.78B
+0.47%+3.52%+8.22%+100.95% 53.49B
-2.06%+2.90%+24.07%+48.36% 45.98B
-1.79%+0.19%+19.32%+123.62% 42.94B
-1.65%+0.96%+237.56%+823.66% 40.08B
-2.26%-4.14%+15.38%+45.53% 33.52B
-4.14%-12.25%+17.81%-8.02% 23.97B
+12.10%+16.60%+55.14%+46.15% 23.67B
Average +0.68%+1.14%+39.87%+128.75% 38.31B
Weighted average by Cap. -0.16%+1.62%+45.37%+149.64%

Financials

2024 2025
Net sales 17.82M 12.71M 11.36M 10.51M 9.52M 1.21B 18.11M 127M 50.04M 632M 47.7M 46.68M 2B 23.59M 16.83M 15.05M 13.92M 12.6M 1.6B 23.98M 168M 66.26M 837M 63.16M 61.81M 2.65B
Net income -1.22M -874K -781K -723K -654K -83.11M -1.24M -8.7M -3.44M -43.47M -3.28M -3.21M -138M -6.01M -4.29M -3.84M -3.55M -3.21M -408M -6.11M -42.7M -16.89M -213M -16.1M -15.75M -676M
Net Debt -7.62M -5.43M -4.86M -4.49M -4.07M -517M -7.74M -54.09M -21.39M -270M -20.39M -19.95M -856M -6.86M -4.89M -4.37M -4.05M -3.66M -465M -6.97M -48.7M -19.26M -243M -18.36M -17.97M -771M
Projected Income Statement - Annual - Devonian Health Group Inc.
Logo Devonian Health Group Inc.
Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various autoimmune fibroinflammatory diseases with novel therapeutic approaches to targeting unmet medical needs. The Company is to develop prescription drugs for the treatment of fibroinflammatory autoimmune diseases including but not limited to atopic dermatitis, radiodermatitis and ulcerative colitis. It is also involved in the development of cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Its Thykamine is an active lead drug candidate with safety and profiles confirmed in several pre-clinical and clinical studies targeting inflammation. Its cosmeceutical products include R-Spinasome and Purgenesis. The Company’s subsidiary, Altius Healthcare LP, focused on selling prescription pharmaceutical products in Canada, under licenses from brand-name pharmaceutical companies.
Employees
10
Date Price Change Volume